Programme Day 2

08.00 – 09.00

Right outside the Registration Area of ECTH2016, at the World Forum

ECTH 5K Run

Join the ECTH run coordinators early on Thursday 29 September 2016 for the ECTH 5K Run. Click here for the route.

The run will begin at 08:00 hrs and consists of one loop through the Scheveningse Bosjes, in English Scheveningen Woods. This is in the surroundings of the World Forum right next to many of the congress hotels. Making it easy to roll out of bed for the start and get back to the congress quickly after the finish. The layout of the woods with its nice pond and wide paths make it ideal for running.

Joining the run is free of charge and you don’t need to register in advance. You will however receive a nice gift when you finish your first ever ECTH 5K Run.

Additionally the ECTH Board will donate 10 EUR per runner to the WakaWaka Foundation, which monitors the responsible and efficient donation of WakaWaka Lights and Powers in humanitarian aid situations in crisis areas like Haiti, Syria, West-Africa, the Philippines and Nepal.

So don’t forget to bring your running shoes to The Hague and we will see you ready to run on Thursday morning.

ECTH run

08.30 – 08.55

Foyer: King Willem-Alexander

Meet the expert

Venous thrombosis treatment, Harry Büller, The Netherlands

Meet the expert

Thrombotic thrombocytopenic purpura, Flora Peyvandi, Italy

Meet the expert

Haemophilia, Peter Collins, United Kingdom

Meet the expert

Women disorders, Saskia Middeldorp, The Netherlands

How to

How to publish? Frits Rosendaal, The Netherlands

How to

How to design a clinical study? Suzanne Cannegieter, The Netherlands

How to

How to produce recombinant proteins? Mettine Bos, The Netherlands

 

How to

How to write a successful grant? Ian Peake, United Kingdom

08.55 – 09.20

Foyer: King Willem-Alexander

Meet the expert

Bleeding disorders, Pier Mannucci, Italy

 

Meet the expert

Von Willebrand disease, Frank Leebeek, The Netherlands

Meet the expert

Diagnosis of Venous Thrombosis, Menno Huisman, The Netherlands

Meet the expert

Thrombophilia, Pierre Morange, France

Meet the expert

Platelets, Bernhard Nieswandt, Germany

How to

How to design morpholinos? Elisabetta Castoldi, The Netherlands

How to

How to do a GWAS? David Trégouët, France

How to

How to do population studies? Sigrid Brækkan, Norway

How to

How to do epitope mapping? Karen Vanhoorelbeke, Belgium

How to

How to study a platelet? Judith Cosemans, The Netherlands

09.30 – 10.30

 

Focus symposium

Vessel wall – Mouse models of vessel wall pathology

Hall: King Willem-Alexander

Focus symposium
Vessel wall – Mouse models of vessel wall pathology

  • Mouse models of vessel wall pathology, Leon Schurgers, The Netherlands
  • Silencing of anticoagulant protein C evokes low incident but spontaneous atherothrombosis in Apolipoprotein E deficient mice, Marco Heestermans, The Netherlands
  • Deletion of chromosome 9p21 noncoding cardiovascular risk interval in mice induces a prothrombotic phenotype, Amel Mohamadi, France
  • Divergent and convergent PAR1,2,3,4 and histamine-induced signal transduction pathways in endothelial cells uncovered by quantitative phosphoproteomics, Bart van den Eshof, The Netherlands

Focus symposium

Bleeding – Regulation of von Willebrand factor by ADAMTS13

Hall: Amazon

Focus symposium
Bleeding – Regulation of von Willebrand factor by ADAMTS13

  • Regulation of von Willebrand factor by ADAMTS13, Jim Crawley, United Kingdom
  • The role of ADAMTS13 exosites in VWF recognition and proteolysis, Anastasis Petri, United Kingdom
  • High and long-term expression of von Willebrand factor after sleeping-beauty transposon-mediated gene therapy in mice, Irina Portier, Belgium
  • Scavenger-receptors LRP1 and SRAI display enhanced association to von Willebrand factor clearance mutants p.R1205H (Vicenza) and p.S2179F, Peter Lenting, France

Focus symposium

Clotting – New approaches to identify genetic risk factors for venous thrombosis

Hall: Mississippi

Focus symposium
Clotting – New approaches to identify genetic risk factors for venous thrombosis

  •  New approaches to identify genetic risk factors for venous thrombosis, Pierre Morange, France
  • Defects of splicing in antithrombin deficiency: much more than expected, Maria Eugenia De La Morena-Barrio, Spain
  • Mild antithrombin deficiency and risk of recurrent venous thrombosis: results from the MEGA follow-up study, Juraj Sokol, Slovakia
  • Genetic risk factors for venous thrombosis in women using combined oral contraceptives: update of the Pilgrim study, Pierre Suchon, France

Focus symposium

Platelets – Developments in the treatment of thrombotic trombocytopenic purpura

Hall: Yangtze 1&2

Focus symposium
Platelets – Developments in the treatment of thrombotic trombocytopenic purpura

  • Developments in the treatment of thrombotic trombocytopenic purpura, Flora Peyvandi, Italy
  • Major thromboembolic events and mortality in acquired thrombotic thrombocytopenic purpura: results from the phase 2 study with caplacizumab, Hilde De Winter, Belgium
  • A novel two-stage  FRETS-VWF73 assay reveals a cryptic pool of ADAMTS13 in plasma, Mirjam Mebius, The Netherlands
  • Childhood-onset acquired thrombotic thrombocytopenic purpura and long-term outcomes: the French reference centre for thrombotic microangiopathies experience, Bérangère Joly, France

10.30 – 11.00

Foyer

Coffee Break & Poster Viewing

11.00 – 12.00

Hall: King Willem-Alexander

State of the Art (11.00-11.30)

 

The contact pathway: an ideal target for antithrombotic therapy

Thomas Renne 

State of the Art (11.30-12.00)

 

Congenital Thrombophilia: new factors and mechanism

Javier Corral 

11.00 – 12.00

Hall: Mississippi

State of the Art (11.00-11.30)

 

Understanding ADAMTS13 and Thrombotic Thrombocytopenic Purpura

Karen Vanhoorelbeke

State of the Art (11.30-12.00)

 

Platelets and chemokines

Meinrad Gawaz

12.00 – 12.15

Foyer

Short Break

12.15 – 13.15

Amazon

 

 

 

Special Symposium (not part of main CME/CPD programme)

Catering is provided

12.15 – 13.15

Yangtze 1&2

 

Special Symposium (not part of main CME/CPD programme)

Catering is provided

13.30 – 14.15

Hall: King Willem-Alexander

Plenary lecture

Antithrombotic Therapy: now and in the future
Harry R. Büller

14.30 – 15.15

 

Oral communications

Vessel wall – Endothelial cells

Hall: King Willem-Alexander

Oral communications
Vessel wall: Endothelial cells

  • Mechanisms of STXBP5 mediated regulation of Weibel-Palade body release, Maaike Schillemans, The Netherlands
  • Effects of dabigatran-etexilate and warfarin on atherosclerotic plaque vulnerability, Rick van Gorp, The Netherlands
  • Targeting coagulation factor Xa by rivaroxaban reduces the onset and progression of atherosclerosis and enhances plaque stability in ApoE null mice, Jelle Posthuma, The Netherlands

Oral communications

Clotting – Venous thrombosis and cancer

Hall: Amazon

Oral communications
Clotting – Venous thrombosis and cancer

  • Venous thromboembolism as a first sign of occult malignancy is associated with an increased risk of recurrent venous thromboembolism, Olga Vikhammer Gran, Norway
  • Thromboembolic events during the treatment of childhood acute lymphoblastic leukaemia, Gonul Aydogan, Turkey
  • Risk of venous thrombo-embolism in female malignancies: the Scandinavian Thrombosis and Cancer Cohort, Inger Lise Gade, Denmark

Oral communications

Clotting – Inflammation

Hall: Mississippi

Oral communications
Clotting – Inflammation

  • Thrombin contributes to protective immunity in pneumonia derived sepsis via fibrin polymerization and platelet-neutrophil interactions, Theodora Claushuis, The Netherlands
  • The role of von Willebrand factor in a malaria-associated lung pathology model, Sirima Kraisin, Belgium
  • Higher prothrombotic activities in M1 than M2 macrophages in atherosclerotic patients, Annabelle Dupont, France

Oral communications

Bleeding – Diagnosis and prognosis

Hall: Yangtze 1&2

Oral communications
Bleeding – Diagnosis and prognosis

  • Predictors of bleeding after low-risk dental procedures in patients on vitamin K antagonists: a cohort study, Joseph Biedermann, The Netherlands
  • Prospective evaluation of bleeding incidence in factor XIII deficiency (Pro-RBD study), Flora Peyvandi, Italy
  • The necessity of refining the diagnostic evaluation of patients with a bleeding tendency not explained by current routine laboratory testing, Caroline Veen, The Netherlands

15.15 – 15.45

Foyer

Coffee Break & Poster Viewing

15.45 – 17.15

Invited integrated symposium

DOACs, antidotes, and bypassing agents

Hall: King Willem-Alexander

Invited integrated symposium
DOACs, antidotes, and bypassing agents

  • The story on dabigatran, to thrombin inhibition and back, Joanne van Ryn, Germany
  • Direct anticoagulants regulate arterial thrombosis, Henri Spronk, The Netherlands
  • Bypassing direct Xa inhibitors by lessons from nature, Pieter Reitsma, The Netherlands

Invited integrated symposium

Targeting platelet receptors – new developments

Hall: Amazon

Invited integrated symposium
Targeting platelet receptors – new developments

  • GPVI/CLEC-2 function in thrombosis and haemostasis, Stephen Watson, United Kingdom
  • Targeting GPIb in acute stroke, Simon de Meyer, Belgium
  • The GPVI competitor Revacept: Preclinical and clinical development, Götz Münch, Germany

Invited integrated symposium

Genetics and complex disease

Hall: Mississippi

Invited integrated symposium
Genetics and complex disease

  • Epidemiolomics of complex diseases: Tools and strategies for new genomics risk factors discovery, David Tregouet, France
  • Genetics of coronary artery disease – discovery and translation, Nilesh Samani, France
  • Risk prediction and missing heritability for multifactorial diseases, Françoise Clerget, France

Invited integrated symposium

Novel therapies in Hemophilia

Hall: Yangtze 1&2

Invited integrated symposium
Novel therapies in Hemophilia

  • Effect of emicizumab – a humanized bispecific antibody mimicking FVIII cofactor function – on a variety of assay systems, Andreas Calatzis, Switzerland
  • Potential benefits of Fc fusion beyond half-life extension, Stefan Lethagen, Sweden
  • Use of anticoagulant inhibitors in hemophilia- benefit and risk – how much we know about them?, Trevor Baglin, United Kingdom

17.15 – 18.45

Poster Session Area

Poster sessions

Vessel wall

Poster sessions
Vessel wall

  • Selective increase of endothelial and cardiomyocyte extracellalar vesicles after experimental myocardial infarction, Jose Paramo, Spain
  • Endogenous plasmin activity in acute thrombotic thrombocytopenic purpura, Claudia Tersteeg, Belgium
  • Identification of the core human endothelial transcriptome using a systems approach, Lynn Butler, Sweden
  • A novel cell-surface proteomics approach identifies IL-1ß and TNFα-induced changes on the endothelial surface and reveals a conformational change in ITGA5, Eelke Béguin, The Netherlands
  • Differential effects of vitamin K antagonists vs direct oral anticoagulants: consequences to the genesis, progression and vulnerability of atherosclerotic plaque, Rick van Gorp, The Netherlands
  • Nestin is a novel endothelial specific protein in the nonproliferative adult human vasculature, and has potential links to cardiovascular disease, Philip Dusart, Sweden

Poster sessions

Platelets: Regulation and mechanisms

Poster sessions
Platelets: Regulation and mechanisms

  • Defective magnesium transport enhances receptor-operated calcium entry in platelets thereby accelerating thrombosis and stroke, Sanjeev Gotru, Germany
  • Deletion of junctional adhesion molecule A from platelets increases early stage neointima formation after wire injury in hyperlipidaemic mice, Rory Koenen, The Netherlands
  • Full activation of mouse platelets requires an ADP secretion pathway regulated by SERCA3 ATPase-dependent calcium stores, Ziane Elaib, France

 

  • Mice lacking GARP on platelets display unaltered thrombus formation, Elien Vermeersch, Belgium
  • TMEM16F-mediated platelet pro-coagulant activity is critical for haemostasis and thrombosis but not for infarct progression after ischaemic stroke, Ayesha Anjum Baig, Germany
  • Evaluation of isoflavonoids antiplatelet potential in relation to their structural modifications, Lenka Applova, Czech Republic

Poster sessions

Platelets: Disease outcomes

Poster session
Platelets: Disease outcomes

  • Elevated levels of neutrophil extracellular traps markers are associated with severity of stroke, Antonio Moscardo, Spain
  • Storage pool disease with mild thrombocytopenia associated with two novel FLI1 mutations, Paul Saultier, France
  • ADAMTS13 reactive CD4+ T-cells in autoimmune thrombotic thrombocytopenic purpura, Fabian Verbij, The Netherlands
  • The role of the endothelium and platelets in the development of neonatal sepsis, Unwana Emagha, Ireland
  • Clinical outcomes of argatroban versus fondaparinux in heparin-induced thrombocytopenia, Fahad Al-Eidan, Saudia Arabia
  • Major cardiovascular events prediction after primary percutaneous coronary intervention: do fibrinogen and von Willebrand factor add value to number of stents and poor anti-platelet therapy response?, Tina Kocica, Serbia

Poster sessions

Bleeding: Basic concepts

Poster sessions
Bleeding: Basic concepts

  • N-acetylcysteine in preclinical animal models for thrombotic thrombocytopenic purpura, Claudia Tersteeg, Belgium
  •  Bleeding tendency measured by thrombin generation in patients with severe vitamin K antagonist overdose, Anna Selmeczi, Hungary

 

  • Identification of a novel mutation in intron 7 of the F8 gene, Shirin Ravanbod, Iran
  • The need for vitamin K antagonists in patients with haemophilia A: nature does not protect all, Marie-Sophie de Koning, The Netherlands
  • Time-dependent biodistribution of  rIX-FP following intravenous application to rats and hemophilia B mice, Marc Nolte, Germany

Poster sessions

Bleeding: New treatments in haemophilia

Poster sessions
Bleeding: New treatments in haemophilia

  • Guardian™5: a multi-centre non-interventional study of safety and efficacy of turoctocog alfa  during long-term treatment of severe and moderately severe haemophilia A (FVIII ≤2%), Nikola Tripkovic, Switzerland
  • The efficacy and safety of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in previously treated children with haemophilia B: results of a Phase 3 pivotal clinical trial, Alex Veldman, Germany
  • Results of a Phase III pharmacokinetics, efficacy and safety study in children less than 12 years of age with severe haemophilia A treated with rVIII-singlechain, Alex Veldman, Germany
  • Pharmacokinetic-guided daily dosing: a significant reduction in weekly clotting factor VIII consumption, Iris van Moort, The Netherlands
  • Long-term safety and efficacy of recombinant factor VIII Fc (rFVIIIFc) for the treatment of severe haemophilia A: European subgroup interim analysis of the ASPIRE study, Bent Winding, Denmark
  • A multicentre international study on perioperative treatment with replacement therapy in haemophilia B: should we B more precise? (Opti-clot studies), Hendrika Hazendonk, The Netherlands

Poster sessions

Bleeding: Consequences of bleeding disorders

Poster sessions
Bleeding: Consequences of bleeding disorders

  • Arthropathy in patients with moderate and severe von Willebrand disease, Karin van Galen, The Netherlands
  • Endothelial injury markers are associated with an increased risk of major bleeding in patients treated with vitamin K antagonists: a case-cohort study, Nienke van Rein, The Netherlands
  • Oral bleeding symptoms and outcome of prophylactic treatment in children with moderate and severe von Willebrand disease – from the WIN study, Johan Boender, The Netherlands
  • Intracranial bleeding as an initial manifestation of haemophilia : long term follow up of inhibitor development, Selin Aytac, Turkey
  • Bleeding symptoms and patterns in recessively inherited coagulation disorders patients versus haemophiliacs, Saqib Ansari, Pakistan
  • The effect of tranexamic acid on blood loss and maternal outcome in the treatment of persistent postpartum haemorrhage: a nationwide cohort study, Johanna van der Bom, The Netherlands

Poster sessions

Clotting: Regulation and Mechanisms

Poster sessions
Clotting: Regulation and Mechanisms

  • Synergistic enhancement of APC association to phospholipids by protein S and activated factor V, Magdalena Gierula, United Kingdom
  • Hepatic tissue factor-mediated intrahepatic fibrin deposition drives liver regeneration after partial hepatectomy in mice, Dafna Groeneveld, The Netherlands
  • Inhibition of coagulation factor Xa attenuates myocardial ischaemia reperfusion injury in mice, Jens Posma, The Netherlands
  • Anti-beta2-glycoprotein I antibodies cause lupus anticoagulant and activated protein C resistance through an interaction with coagulation factor V, Jessica Molhoek, The Netherlands
  • Evaluation of global coagulation balance among PMM2-congenital disorder of glycosylation patients, using thrombin generation assay, Tiffany Pascreau, France
  • Genetic determinants of thrombin generation and clot lysis time: results of a targeted exome sequencing study, Hugoline de Haan, The Netherlands

Poster sessions

Clotting: Arterial disease

Poster sessions
Clotting: Arterial disease

  • Myocardial infarction and future risk of cancer in the general population – the Tromsø study, Ludvig Balteskard Rinde, Norway
  • Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease, Frederik Denorme, Belgium
  • Procoagulant state in young females with severe early-onset obesity, Satu Långström, Finnland
  • Coagulation factor VIII, white matter lesions, and cognition in the Cardiovascular Health Study, Jessica Rohmann, Germany
  • Assessment of platelet function by thromboelastography-based platelet mapping in cardiac patients on aspirin and clopidogrel, Anupam Verma, India
  • Intrinsic coagulation antigen and activation levels, headache and the risk of young ischaemic stroke, Hine van Os, Germany

Poster sessions

Clotting: Venous thrombosis

Poster sessions
Clotting: Venous thrombosis

  • Annexin M2 haplotype and adverse pregnancy outcomes – a perfect match?, Rita Tenreiro, Portugal
  • Venous thromboembolism predictive capability of genetic risk scores in subjects  with a family history of venous thromboembolism, Maria Farm, Spain
  • Association of disease prevalence and failure rate in diagnostic management studies in suspected pulmonary embolism: towards a new tailored standard for future studies, Charlotte Dronkers, The Netherlands
  • Homocysteine levels and risk of first venous thrombosis: the influence of (unmeasured) confounding factors, Willem Lijfering, The Netherlands
  • Homozygous prothrombin 20210A mutation among children with deep venous thrombosis, Selin Aytac, Turkey
  • Long-term clinical implications of residual pulmonary vascular obstruction after pulmonary embolism: a ventilation-perfusion lung scan follow-up study at two timepoints, Romain Chopard, France

Poster sessions

Clotting: Venous thrombosis, cancer and medical conditions

Poster sessions
Clotting: Venous thrombosis, cancer and medical conditions

  • Preeclampsia and risk of a first and recurrent venous thromboembolism, Luuk Scheres, The Netherlands
  • Performance of the Khorana score in patients with pancreatic cancer, Saskia Middeldorp, The Netherlands
  • The effect of GPVI rs1613662 and platelet count on cancer-related venous thromboembolism, Olga Vikhammer Gran, Norway
  • Hospital-related first venous thrombosis and risk of recurrence, Esben Bjøri, Norway
  • Effect of tumoral lysis on the haemostatic system: parallel and massive increase of circulating DNA and D-dimer without significant changes in anticoagulants: relationship to the risk of thrombosis, Raquel López-Gálvez, Spain

19.30 – 00.00

The Gemeentemuseum (Offsite)

Congress dinner

 

Congress dinner

Don’t miss out on the opportunity to network with the largest contingent of experts in thrombosis and haemostasis during the official congress dinner: a good place to meet colleagues and friends. The Gemeentemuseum Den Haag, one of the most characteristic museums of The Netherlands, will be the venue.

The Gemeentemuseum is a refreshing museum with an unexpected twist. The fabulous setting of the 1935 Art Deco building designed by top Dutch architect H. P. Berlage will make the dinner a truly outstanding experience. With almost 300 works, the Gemeentemuseum’s Mondriaan collection is unique in the world. The exhibition also contains his last – unfinished – masterpiece, the Victory Boogie Woogie (1942-1944).

It is a mere 10-minute walk from the World Forum to the Gemeentemuseum.

this_is_a_fabulous_one